Is Eterna Therapeutics Inc (ERNA) overvalued? · P/E 0.0, rev $582.0K
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
This page asks whether Eterna Therapeutics Inc (ERNA) looks expensive on cached numbers — not a short thesis.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
ERNA currently screens at market cap $6.9M and trailing P/E 0.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ERNA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ERNA stock page for the full model, not this heading.
Not investment advice.